Talphera (TLPH) Asset Writedowns and Impairment (2015 - 2023)
Talphera's (TLPH) quarterly Asset Writedowns and Impairment came in at $1.1 million in Q1 2023, up 1009.38% quarter-over-quarter from $96000.0 in Q4 2019.
Talphera (TLPH) Asset Writedowns and Impairment (2015 - 2023) Analysis & Trends
Talphera's Asset Writedowns and Impairment history runs 3 years deep, the most recent figure standing at $1.1 million for Q1 2023.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $1.1 million in Q1 2023; TTM through Dec 2023 was $1.1 million, a N/A change from a year earlier, with the FY2023 full-year figure at $6.9 million, changed N/A from the prior year.
- Asset Writedowns and Impairment rose to $1.1 million in Q1 2023 per TLPH's latest filing, from $96000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $1.1 million in Q1 2023 and bottomed at $96000.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.74 Bn | 86.88 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.87 Bn | 32.13 Bn | 1.97 Bn |
| 3 | Zoetis | 32.28 Bn | 30.34 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.14 Bn | 20.98 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - |
| 7 | Viatris | 20.25 Bn | 18.44 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.89 Bn | 16.57 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn |
| 10 | Talphera | 93.55 Mn | 93.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 1.07 Mn |
| Mar 31, 2023 | 1.07 Mn |
| Dec 31, 2019 | 96,000.00 |
| Dec 31, 2019 | 96,000.00 |
| Sep 30, 2019 | 900,000.00 |
| Sep 30, 2019 | 900,000.00 |
| Sep 30, 2015 | 500,000.00 |
| Sep 30, 2015 | 500,000.00 |